Histone Deacetylase Inhibition Attenuates Cardiac Hypertrophy and Fibrosis through Acetylation of Mineralocorticoid Receptor in Spontaneously Hypertensive Rats

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Pharmacology

• Publication date

  2015-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/mol.114.096974PMID 25667225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension

  2013cited by this paper
• Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo

  2013cited by this paper
• Tissue-Specific Upregulation of Angiotensin-Converting Enzyme 1 in Spontaneously Hypertensive Rats Through Histone Code Modifications

  2012cited by this paper
• Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

  2012cited by this paper
• Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

  2012cited by this paper
• Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy

  2011cited by this paper
• Acetylation and nuclear receptor action.

  2011cited by this paper
• The biology of lysine acetylation integrates transcriptional programming and metabolism

  2011influential reference
• HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats

  2010influential reference
• Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.

  2010cited by this paper
• Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy.

  2010cited by this paper
• Antifibrotic activity of an inhibitor of histone deacetylases in DOCA‐salt hypertensive rats

  2010influential reference
• Exaggerated Blood Pressure Variability Superimposed on Hypertension Aggravates Cardiac Remodeling in Rats via Angiotensin II System-Mediated Chronic Inflammation

  2009cited by this paper
• Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy.

  2009cited by this paper
• The mineralocorticoid receptor and its coregulators.

  2009cited by this paper
• Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition.

  2009cited by this paper
• Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications

  2009cited by this paper
• Chromatin immunoprecipitation scanning identifies glucocorticoid receptor binding regions in the proximal promoter of a ubiquitously expressed glucocorticoid target gene in brain

  2008cited by this paper
• The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

  2007cited by this paper
• Mineralocorticoid receptor activation and cardiac fibrosis.

  2007cited by this paper
• HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

  2007influential reference
• Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?

  2007influential reference
• Cross-talk between Histone Modifications in Response to Histone Deacetylase Inhibitors

  2007cited by this paper
• Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor.

  2006cited by this paper
• Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy

  2006cited by this paper
• Post-translational modifications of steroid receptors.

  2006cited by this paper
• Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression

  2006cited by this paper
• Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes.

  2005cited by this paper
• Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding

  2005cited by this paper
• Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats.

  2005cited by this paper
• A Serine/Threonine-rich Motif Is One of Three Nuclear Localization Signals That Determine Unidirectional Transport of the Mineralocorticoid Receptor to the Nucleus*

  2005cited by this paper
• Inhibition of NF-κB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats

  2005cited by this paper
• Pressure-Independent Effects of Angiotensin II on Hypertensive Myocardial Fibrosis

  2004cited by this paper
• Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes.

  2004cited by this paper
• Matricellular proteins in the heart: possible role during stress and remodeling.

  2004cited by this paper
• Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.

  2004cited by this paper
• Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study.

  2003cited by this paper
• Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

  2003cited by this paper
• Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors*

  2003cited by this paper
• Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor*

  2002cited by this paper
• Aldosterone and PAI-1: implications for renal injury.

  2002cited by this paper
• Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity*

  2001cited by this paper
• Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy.

  2001cited by this paper
• p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation*

  2000cited by this paper
• A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

  2000cited by this paper
• Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis.

  2000cited by this paper
• Modulation of human mineralocorticoid receptor function by protein kinase A.

  1999cited by this paper
• Roles of histone acetyltransferases and deacetylases in gene regulation

  1998cited by this paper
• Homodimer formation is rate-limiting for high affinity DNA binding by glucocorticoid receptor.

  1992cited by this paper
• Glucocorticoid-mediated induction of alpha 1-acid glycoprotein: evidence for hormone-regulated RNA processing.

  1984cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• Cardio-Vascular Extracellular Matrix: The Unmet Enigma

  2026cites this paper
• Epigenetic Drugs Splitomicin, Suberohydroxamic Acid, CPTH6, BVT-948, and PBIT Moderate Fibro-Fatty Development in Arrhythmogenic Cardiomyopathy

  2025cites this paper
• Epigenetic Therapeutics in Human Heart Failure.

  2025cites this paper
• Epigenetic Mechanisms in Heart Diseases

  2025cites this paper
• HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease

  2025cites this paper
• Single-cell RNA sequencing reveals the potential role of Postn(+) fibroblasts in promoting the progression of myocardial fibrosis after myocardial infarction

  2025cites this paper
• Contribution of histone deacetylases (HDACs) to the regulation of histone and non-histone proteins: implications for fibrotic diseases

  2025cites this paper
• The Role of Cardiac Fibroblast Heterogeneity in Myocardial Fibrosis and Its Novel Therapeutic Potential

  2025cites this paper
• Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

  2025cites this paper
• Role of Gut Microbial Metabolites in Ischemic and Non-Ischemic Heart Failure

  2025cites this paper
• New Types of Post-Translational Modification of Proteins in Cardiovascular Diseases

  2025cites this paper
• Exploring the Impact of Microgravity on Gene Expression: Dysregulated Pathways and Candidate Repurposed Drugs

  2025cites this paper
• Cardiovascular comorbidities in Chinese inpatients with schizophrenia spectrum disorders

  2025cites this paper
• Pharmacological inhibition of histone deacetylase alleviates chronic unpredictable stress induced atherosclerosis and endothelial dysfunction via upregulation of BDNF.

  2024cites this paper
• The role of the gut microbiota in the onset and progression of heart failure: insights into epigenetic mechanisms and aging

  2024cites this paper
• Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives

  2024cites this paper
• Role of histone deacetylase inhibitors in non-neoplastic diseases

  2024cites this paper
• Targeting histone deacetylases for heart diseases.

  2023cites this paper
• Therapeutic potential of melatonin in targeting molecular pathways of organ fibrosis

  2023cites this paper
• miRNAs Epigenetic Tuning of Wall Remodeling in the Early Phase after Myocardial Infarction: A Novel Epidrug Approach

  2023cites this paper
• Comparative Metabolomics in Single Ventricle Patients after Fontan Palliation: A Strong Case for a Targeted Metabolic Therapy

  2023cites this paper
• Review: Acetylation Mechanisms andTargeted Therapies in Cardiac Fibrosis.

  2023cites this paper
• Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

  2023cites this paper
• Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

  2022cites this paper
• Targeting cancers and metabolic disorders: The prospects of combining HDAC8 inhibitor and activator

  2022cites this paper
• A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid

  2022cites this paper
• Short-Chain Fatty Acids in Gut–Heart Axis: Their Role in the Pathology of Heart Failure

  2022cites this paper
• Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood

  2022cites this paper
• A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors

  2022cites this paper
• Critical Functions of Histone Deacetylases (HDACs) in Modulating Inflammation Associated with Cardiovascular Diseases

  2022cites this paper
• Inhibition of the cardiac fibroblast-enriched histone methyltransferase Dot1L prevents cardiac fibrosis and cardiac dysfunction

  2022cites this paper
• Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials

  2022cites this paper
• Molecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy

  2021cites this paper
• Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19

  2021cites this paper
• Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway

  2021cites this paper
• Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging

  2021cites this paper
• Chronic HDAC6 Activation Induces Atrial Fibrillation Through Atrial Electrical and Structural Remodeling in Transgenic Mice.

  2021cites this paper
• Pretreatment with valproic acid alleviates pulmonary fibrosis through epithelial–mesenchymal transition inhibition in vitro and in vivo

  2021cites this paper
• Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.

  2021cites this paper
• Current therapies in Nephrotic Syndrome: HDAC inhibitors, an Emerging Therapy for Kidney Diseases

  2021cites this paper
• Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: the glycyrrhetinic acid-like factor (GALF) hypothesis.

  2021cites this paper
• Hidden pharmacological activities of valproic acid: A new insight.

  2021cites this paper
• Structural and molecular determinants of mineralocorticoid receptor signalling

  2021cites this paper
• Acetylation in cardiovascular diseases: Molecular mechanisms and clinical implications.

  2020cites this paper
• New drug targets for hypertension: A literature review.

  2020cites this paper
• Therapeutic effects of histone deacetylase inhibitors on heart disease

  2020cites this paper
• Histone modification as a potential preventative and therapeutic approach for cardiovascular disease

  2020cites this paper
• Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications

  2020cites this paper
• Cardioprotection by AN-7 a prodrug of the histone deacetylase inhibitor butyric acid: Selective activity in hypoxic cardiomyocytes and cardiofibroblasts.

  2020cites this paper
• Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis

  2019cites this paper
• Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy.

  2019cites this paper
• HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis

  2019cites this paper
• Spotlight on epigenetic reprogramming in cardiac regeneration.

  2019cites this paper
• Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Mineralocorticoid Receptors, Neuroinflammation and Hypertensive Encephalopathy

  2018cites this paper
• Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification

  2018influential citation
• The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor

  2018cites this paper
• Manipulating the epigenome for the treatment of disorders with thrombotic complications.

  2018cites this paper
• The effect of melatonin on cardio fibrosis in juvenile rats with pressure overload and deregulation of HDACs

  2018cites this paper
• Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure

  2018cites this paper
• Upregulation of C/EBPβ and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA‐induced hypertrophy

  2018cites this paper
• ClC-3 chloride channel is involved in isoprenaline-induced cardiac hypertrophy.

  2018cites this paper
• Inhibition of HDAC enhances STAT acetylation, blocks NF- (cid:2) B, and suppresses the renal inflammation and fibrosis in Npr1 haplotype male mice

  2017cites this paper
• Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome

  2017cites this paper
• Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload

  2017cites this paper
• Histone 3 modifications and blood pressure in the Beijing Truck Driver Air Pollution Study

  2017cites this paper
• Inhibition of HDAC enhances STAT acetylation, blocks NF-κB, and suppresses the renal inflammation and fibrosis in Npr1 haplotype male mice.

  2017cites this paper
• Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy

  2017cites this paper
• Evidence of epigenetic tags in cardiac fibrosis.

  2017cites this paper
• Roles of HDAC2 and HDAC8 in Cardiac Remodeling in Renovascular Hypertensive Rats and the Effects of Valproic Acid Sodium

  2016cites this paper
• Pharmacology of heart failure: From basic science to novel therapies.

  2016cites this paper
• Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate Angiotensin II-induced cardiac fibroblast migration and proliferation

  2016cites this paper
• Epigenetic and Nongenomic Roles for Histone Deacetylases in Heart Failure

  2016cites this paper
• Studies of lurasidone for bipolar depression show differing results

  2016cites this paper
• Epigenetic factors MeCP2 and HDAC6 control α-tubulin acetylation in cardiac fibroblast proliferation and fibrosis

  2016cites this paper
• Emerging Hyperkalemia Following Valproic Acid Use in an Elderly Patient With Late-Onset Mania.

  2016cites this paper
• Histone Deacetylase 6-Controlled Hsp90 Acetylation Significantly Alters Mineralocorticoid Receptor Subcellular Dynamics But Not its Transcriptional Activity.

  2016cites this paper
• Histone deacetylase inhibition, but not a mineralocorticoid receptor antagonist spironolactone, attenuates atypical transcription by an activating mutant MR (MRS810L)

  2016cites this paper
• Improvement of oral contraceptive-induced glucose dysregulation and dyslipidemia by valproic acid is independent of circulating corticosterone

  2016cites this paper
• Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.

  2016cites this paper
• Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats

  2016cites this paper
• Hyperkalemia associated with valproic acid

  2016cites this paper
• 4-PBA prevents pressure overload-induced myocardial hypertrophy and interstitial fibrosis by attenuating endoplasmic reticulum stress.

  2015cites this paper
• Functional Role of G9a Histone Methyltransferase in Cancer

  2015cites this paper
• Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.

  2015cites this paper
• Metabolic control of cell adhesion and migration through beta1A integrin acetylation : be aware of the acetylation switch!

  2015cites this paper
• Combined oral contraceptive synergistically activates mineralocorticoid receptor through histone code modifications.

  1986cites this paper